|
|
|
|
|
|
|
|
|
|
|
| Experimental Information | |
| Enzymatic Activity | |
| Molecule Id | EGIN0000003 |
| PMID | 21306821 |
| Assay Used | Enzymatic and Cell growth inhibition assay |
| Experimently Validated | Yes |
| EGFR (IC50) | - |
| HER2 (IC50) | - |
| HER4 (IC50) | - |
| Mutant L858R (IC50) | - |
| Mutant T790M (IC50) | - |
| Double Mutant (IC50) | - |
| Average ERBB2 and ERBB1 (IC50) | - |
| Inhibition EGFR (%) | - |
| Inhibitory Concentration | - |
| Inhibition HER2 (%) | - |
| Inhibitory Concentration | - |
| Ki (EGFR) | - |
| Ki (HER2) | - |
| Ki (HER4) | - |
| Kd (EGFR) | - |
| Kd (L858R) | - |
| Kd (T790M) | - |
| Kd (L858R/T790M) | - |
| Kd (Other mutation) | - |
| Note | The paper describes the Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor,alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer |
| Extra | - |
| Cellular Activity | ||||||||||||||
| S.No. | Cell Line | Desp. | IC50 | IC80 | ED50 | GI50 | GI90 | EC50 | Kd | Inhibition (%) | Inhibitory Conc. | |||
| 1 | AGS | KRAS mt | > 10000 nM | - | - | - | - | - | - | - | - | |||
| 2 | N87 | HER2 amp | 10 ± 1 nM | - | - | - | - | - | - | - | - | |||
| 3 | SNU1 | KRAS mt | 1950 ± 54 nM | - | - | - | - | - | - | - | - | |||
| 4 | SNU16 | FGFR2 amp | 1520 ± 69 nM | - | - | - | - | - | - | - | - | |||
| 5 | SNU216 | HER2 amp | 20 ± 3 nM | - | - | - | - | - | - | - | - | |||
| 6 | SNU484 | - | 990 ± 14 nM | - | - | - | - | - | - | - | - | |||
| 7 | SNU5 | MET amp | > 10000 nM | - | - | - | - | - | - | - | - | |||
| 8 | SNU601 | KRAS mt | 3700 ± 148 nM | - | - | - | - | - | - | - | - | |||
| 9 | SNU620 | - | 1390 ± 240 nM | - | - | - | - | - | - | - | - | |||
| 10 | SNU638 | MET amp | 4940 ± 326 nM | - | - | - | - | - | - | - | - | |||
| 11 | SNU668 | KRAS mt | > 10000 nM | - | - | - | - | - | - | - | - | |||
| 12 | SNU719 | - | > 10000 nM | - | - | - | - | - | - | - | - | |||
| Activity against Receptor | |
| EGFR | Yes |
| HER2 | Yes |
| HER4 | Yes |
| Wild type | Yes |
| Mutant | - |
| Inhibitor Binding | |
| EGFR | - |
| HER2 | - |
| HER4 | - |